Diala Ezzeddine

Diala Ezzeddine has a diverse work experience spanning multiple industries. Diala is currently a co-founder and Chief Operating Officer at Differentiated Therapeutics, a position they have held since 2021. Prior to this, they served as the CEO of Airbase Breathing Company starting in 2020. In the same year, they also worked as a Principal at InPact Bio.

From 2016 to 2020, Diala served as the CEO of Xios Therapeutics. Before that, they held executive roles at X-Chem, Inc. where they were the Executive Vice President & Chief Business Officer in 2015 and the Chief Business Officer from 2010 to 2014. In 2010, they were a Senior Business Advisor at X-Body, Inc.

Diala's earlier career includes positions as the Head of Business Development at Archemix Corp from 2008 to 2009, a Consultant at BioAssets Development Corp. from 2007 to 2008, and as the Co-founder & CEO of HydroSpine, Inc. from 2006 to 2007.

Diala'scareer began at Millennium Pharmaceuticals, Inc. where they worked in Business Development from 1999 to 2004. This extensive work experience enables Diala to bring a wealth of knowledge and leadership to their current role at Differentiated Therapeutics.

Diala Ezzeddine has a Ph.D. in Genetics from Harvard Medical School. Diala also holds an MS in Biology from Boston University and a BS in Biology/Geology from the American University of Beirut in Lebanon. Additionally, they have completed the Boardroom Ready Program and graduated from Women In Bio - Engage. Educate. Empower. in October 2018. Diala Ezzeddine has also attended École des Roches and Collège Protestant Français de Beyrouth, although no specific degrees or fields of study were mentioned for these institutions.